Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TERN

TERN - Terns Pharmaceuticals, Inc. Stock Price, Fair Value and News

$52.93-0.01 (-0.02%)
Market Closed

11/100

TERN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

TERN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TERN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TERN Price Action

Last 7 days

0.2%

Last 30 days

0.1%

Last 90 days

54.8%

Trailing 12 Months

1601.9%

TERN RSI Chart

TERN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TERN Valuation

Market Cap

6.1B

Price/Earnings (Trailing)

-63.45

Price/Sales (Trailing)

418.35

EV/EBITDA

-58.4

Price/Free Cashflow

-74.28

TERN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TERN Fundamentals

TERN Revenue

Revenue (TTM)

14.6M

Rev. Growth (Yr)

7.58%

Rev. Growth (Qtr)

41.9%

TERN Earnings

Earnings (TTM)

-96.2M

Earnings Growth (Yr)

-8.13%

Earnings Growth (Qtr)

4.32%

TERN Profitability

EBT Margin

-655.38%

Return on Equity

-9.56%

Return on Assets

-9.39%

Free Cashflow Yield

-1.35%

TERN Investor Care

Shares Dilution (1Y)

32.21%

Diluted EPS (TTM)

-1.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202513.8M14.2M14.3M14.6M
202413.0M13.1M13.2M13.3M
20234.7M7.9M012.9M
2022228.0K387.0K837.0K2.1M
20210118.0K117.0K170.0K
20200000
Get all data in R, Python etc through our Historical Stock Data APIs

About Terns Pharmaceuticals, Inc.

TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
 WEBSITEternspharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES46

Terns Pharmaceuticals, Inc. Frequently Asked Questions

TERN is the stock ticker symbol of Terns Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Apr 29 2026, market cap of Terns Pharmaceuticals, Inc. is 6.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Apr 29 2026, TERN's PE ratio (Price to Earnings) is -63.45 and Price to Sales (PS) ratio is 418.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TERN PE ratio will change depending on the future growth rate expectations of investors.